GenFleet Therapeutics (Shanghai) Inc. (HKG:2595)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Biopharmaceutical Research and Development	130.27M	104.70M	73.73M
Total	130.27M	104.70M	73.73M

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
United States	130.27M	104.70M	-
Chinese Mainland	-	-	71.78M
Overseas	-	-	1.96M
Total	130.27M	104.70M	73.73M

Data Source: S&P Global Market Intelligence Last updated: Sep 16, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 16, 2026

Data Sources Report a data error